Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience
Recommended Citation
Morgan JA, Go PH, Xuereb L, Kaur B, Akrawe S, Nemeh HW, Borgi J, Lanfear DE, Williams CT, Paone G. Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9-Year Experience. Ann Thorac Surg. 2016 Oct;102(4):1266-73.
Document Type
Article
Publication Date
10-1-2016
Publication Title
The Annals of thoracic surgery
Abstract
BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) have become the standard of care for patients with advanced heart failure. The goal of this study was to review our 9-year institutional experience.
METHODS: From March 2006 through May 2015, 231 patients underwent implantation of 240 CF LVADs, HeartMate II LVAD (Thoratec Corp., Pleasanton, CA; n = 205) or HVAD (HeartWare Inc., Framingham, MA; n = 35). Of these, 127 devices (52.9%) were implanted as bridge to transplantation (BTT) and 113 (47.1%) as destination therapy (DT).
RESULTS: Mean age was 51.2 ± 11.9 years for BTT patients and 58.2 ± 11.4 years for DT patients (p < 0.001). There was a higher incidence of preoperative diabetes, renal insufficiency, peripheral vascular disease, and previous cardiac operation in DT patients (p < 0.05). Survival was higher for BTT patients, with 1-, 6-, 12-, and 24-month survivals of 91.0%, 90.0%, 88.5%, and 72.1%, respectively, versus 85.3%, 81.1%, 75.6%, and 59.0%, respectively, for DT patients (p = 0.038). Gastrointestinal bleeding was the most common complication (29.6%), followed by right ventricular failure (22.5%) and stroke (15.0%), with a similar incidence for BTT and DT patients. Preoperative liver biopsy (hazard ratio [HR] 2.27, p = 0.036), mechanical support (HR 1.82, p = 0.025), aspartate transaminase (HR 1.07, p = 0.001), and alanine aminotransferase (HR 0.95, p = 0.024) were severe independent predictors of survival in multivariate analysis.
CONCLUSIONS: These data indicate excellent survival for BTT and DT patients on long-term LVAD support. However, for LVAD therapy to become a plausible alternative to heart transplantation, we need to further decrease the incidence of postoperative complications.
Medical Subject Headings
Adult; Databases, Factual; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Heart-Assist Devices; Hemodynamics; Humans; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Operative Time; Predictive Value of Tests; Proportional Hazards Models; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Treatment Outcome
PubMed ID
27173072
Volume
102
Issue
4
First Page
1266
Last Page
1273